Robotics company Multiply Labs has partnered with global life-sciences service provider Genscript Biotech to automate the cell isolation phase in cell therapy manufacturing.
This collaboration introduces the first fully automated solution for bead-based cell isolation, utilising Multiply Labs’ cell therapy robotic cluster and GenScript’s cell isolation solution, CytoSinct 1000.
The automated cell isolation technology is designed to handle up to 120×10^9 total cells within an hour, streamlining a traditionally laborious phase of cell therapy manufacturing.
This innovative approach is expected to reduce the complexity of cell isolation without requiring manufacturers to alter their existing processes.
Multiply Labs said the technology could minimise human error and increase output, allowing manufacturing operators and scientists to manage multiple therapies simultaneously.
GenScript Life Science Group president Ray Chen said: “Our collaboration with Multiply Labs marks a significant advancement in personalised medicine and the potential impact of cell therapies.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
“By automating our industry-leading solution, we can dramatically increase productivity and scale operations to unprecedented levels.”
Multiply Labs co-founder and CEO Fred Parietti said: “This collaboration advances our goal of a fully automated, end-to-end cell therapy manufacturing process, reducing costs and expanding patient access to life-changing treatments.”
The automation of cell isolation is said to be a key step in enhancing the efficiency and scalability of cell therapies.
Last year, Genscript Biotech signed a collaboration agreement with T-MAXIMUM Biotech to develop chimeric antigen receptor T cell therapy.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
